Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 201-214

  Takanaga, Hitomi ^a,b   Ohnishi, Ayako ^a,b   Murakami, Hideyasu ^a,b   Matsuo, Hirotami ^a,b   Higuchi, Shun ^a,b   Urae, Akinori ^a,b   Irie, Shin ^a,b   Furuie, Hidetoshi ^a,b   Matsukuma, Kyoko ^a,b   Kimura, Miyuki ^a,b   Kawano, Koichi ^a,b   Orii, Yoshimitsu ^a,b   Tanaka, Toshiaki ^a,b   Sawada, Yasufumi ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NISOLDIPINE;

ADULT; ARTICLE; CITRUS FRUIT; DIASTOLIC BLOOD PRESSURE; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0034065527     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104215     Document Type: Article

References (42)

1. 1. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
2. 2. Bailey DG, Malcom J, Arnold O, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53:637-42.
3. 3. Lundahl J, Regardh CG, Edgar B, Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995;49:61-7.
4. 4. Lundahl J, Regardh CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 1998;54:75-81.
5. 5. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion: pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52:139-45.
6. 6. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-8.
7. 7. Fuhr U, Maier-Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998;36:126-32.
8. 8. Soons PA, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991:50:394-403.
9. 9. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-8.
10. 10. Proppe DG, Hoch OD, McLean AJ, Visser KE. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function [letter]. Br J Clin Pharmacol 1995;39:337-8.
11. 11. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
12. 12. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998;23:55-9.
13. 13. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
14. 14. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.
15. 15. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355-9.
16. 16. Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matthey K, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996;53:41-7.
17. 17. Fuhr U, Klittich K, Atab AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993;35:431-6.
18. 18. Westveer MK, Farquhar ML, George P, Mayers JT. Coadministration of grapefruit juice increases tacrolimus levels in liver transplant recipients. Presented at the 15th Annual Meeting of the American Society of Transplant Physicians. Thorofare (NJ): American Society of Transplantation; 1996;202:115.
19. 19. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
20. 20. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
21. 21. Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998;64:286-8.
22. 22. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64:655-60.
23. 23. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993;54:589-94.
24. 24. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46: 101-10.
25. 25. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13:129-34.
26. 26. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
27. 27. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents, decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
28. 28. Takanaga H, Ohnishi A, Yamada S, Uchida J, Matsuo H, Morimoto S, et al. Effect of grapefruit juice and other juices in P-glycoprotein function of drug absorption in the intestine. Xenobiotic Metab Dispos 1998;13(suppl):S110-1.
29. 29. Edwards DJ, Bellevue III, FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-90.
30. 30. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9.
31. 31. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furanocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391-6.
32. 32. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
33. 33. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. P-Glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 1993;324:99-102.
34. 3H]vinblastine transport by isolated vesicles. Biochim Biophys Acta 1991;1061:106-10.
35. 35. Takanaga H, Ohnishi A, Murakami H, Matsuo H, Sawada Y. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000;49:49-58.
36. 36. Azuma J, Yamamoto I, Watase T, Orii Y, Tanigawa T, Terashima S, et al. Effects of grapefruit juice on the pharmacokinetics of the calcium channel blockers nifedipine and nisoldipine. Curr Ther Res 1998;59:619-33.
37. 37. van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DD. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 1988;43:332-41.
38. 38. Christensen FN, Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol 1985;37:91-5.
39. 39. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981;4:879-85.
40. 40. Edgar B, Bailey D, Bergstrand R, Johnsson G, Lurje L. Formulation dependent interaction between felodipine and grapefruit juice [abstract]. Clin Pharmacol Ther 1990;47:181.
41. 41. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of inter intestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62.
42. 42. Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991;50:394-403.